← Back to Search

Neurotoxin

DAXI 240 U for Plantar Fibroma

Phase 2
Waitlist Available
Research Sponsored by Revance Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks

Summary

The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Eligible Conditions
  • Plantar Fibroma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvement in the American Orthopaedic Foot and Ankle Score (AOFAS)
Secondary study objectives
Reduction in the visual analog pain score for the foot

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DAXI 240 UExperimental Treatment1 Intervention
DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
Group II: PlaceboPlacebo Group1 Intervention
Placebo Intramuscular injection

Find a Location

Who is running the clinical trial?

Revance Therapeutics, Inc.Lead Sponsor
30 Previous Clinical Trials
6,538 Total Patients Enrolled
Wake Forest University Health SciencesOTHER
1,389 Previous Clinical Trials
2,547,019 Total Patients Enrolled
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top